Emami Ltd Strong Q3FY26 Performance Driven by Double-Digit Growth

Emami Limited reported strong Q3FY26 performance with double-digit growth. Consolidated Net Sales at ₹1,147 crore grew by 11%. Domestic Business grew by 11% with 9% volume growth. The Board declared a second interim dividend of 600%, amounting to ₹6 per share for FY26. The company remains focused on purposeful innovation, premiumization, and building future scale.

Q3FY26 Financial Highlights

Emami Limited announced a robust financial performance for the third quarter of fiscal year 2026. Key highlights from the announcement include:

  • Consolidated Net Sales at ₹1,147 crore, reflecting an 11% growth.
  • Revenue from Operations at ₹1,152 crore, up by 10%.
  • Domestic Business grew by 11% with a volume increase of 9%.
  • International Business showed growth of 9%.
  • Gross Margins improved to 70.6%, an increase of 30 bps.
  • EBIDTA at ₹384 crore, grew by 13%; EBIDTA Margins expanded by 110 bps to 33.4%.
  • PBT before Exceptional Items at ₹355 crore, up by 18%.
  • Profit after Tax at ₹319 crore, reflecting a 15% increase.

Dividend Announcement

The Board of Directors has declared a second interim dividend of 600%, which translates to ₹6 per share for FY26.

Strategic Performance and Outlook

The company’s performance in Q3FY26 reflects its strategic priorities focused on innovation and premiumization. Management commentary highlighted that Q3FY26 delivered strong, broad-based performance, with sales growth of 11% driven by healthy volume expansion of 9%. The company’s effective cost discipline and judicious pricing actions led to gross margin expansion. Emami remains committed to strengthening core brands and investing in new-age growth opportunities.

Brand Performance Highlights

Key brand performances and initiatives detailed in the announcement include:

  • BoroPlus: Strong growth led by winter portfolio with multiple product launches.
  • Pain Management Range: Positive momentum across the overall portfolio and healthy growth in recent Balms.
  • Healthcare Range: Strong growth in Zandu Chyawanprash, Honey and Ayurvedic Cough Syrup.
  • Kesh King: Revamped Proposition, Product, Packaging & Price, with new TVCs and advanced hair growth serum launch.

The omnichannel strategy continues to deliver results with organized channels contributing approximately 32% of year-to-date revenues, reflecting an increase of 280 basis points over the previous year.

Source: BSE

Previous Article

Glenmark Transcript of Earnings Call for Q3 & Nine Months Ended December 2025

Next Article

Emami Limited Strong Q3FY26 Performance Driven by Double-Digit Growth